Secarna Pharmaceuticals GmbH & Co. KG

Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in a variety of therapeutic indications. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, to develop highly specific, safe, and efficacious antisense therapies for challenging or currently not druggable targets.

Combining technical capabilities with antisense drug discovery and development expertise, a global KOL network and the Company’s validated partnership model, Secarna is paving the path for a new generation of ASO therapeutics.



Secarna Pharmaceuticals at a glance:

Field of Activity Discovery and development as well as testing and selecting of highly specific, safety-optimizied and efficacious third generation ASOs for pre-clinical and clinical development in immuno-oncology, ophthalmology, immunology, fibrotic diseases (airways, liver, kidney), and anti-viral applications.
Ownership Structure and Financing Privately owned. Investors include UBG Unternehmensberatung & Betreuung and Engelhard Arzneimittel.
Partners Secarna’s objective is to form strategic partnerships leveraging the strengths of the Company and its partners to produce maximum value for the benefit of the alliances throughout their lifetimes. Secarna’s LNAplusTM platform and ASOs have been validated by in-house projects and in collaborations with academic and industry partners (recently: MetP Pharma, Firebrand Therapeutics, undisclosed major pharmaceutical company).
Unique Selling Point Secarna’s proprietary, customized, in-house ASO drug discovery platform LNAplusTM encompasses all aspects of antisense drug discovery and pre-clinical development. It has proven to be fast, reliabe, scalable, efficient and to provide for a uniquely integrated workflow. The platform includes a powerful proprietary bioinformatics screening system, best-in class high throughput screening, and bespoke target-specific functional assays. With that, Secarna can generate and deliver highly specific, safe and efficacious antisense therapies for challenging or currently not druggable targets. The team seeks to establish ASO therapeutics as the third pillar in drug development next to small molecules and antibodies.
Date of Incorporation/Number of Employees 2015/15



Jonas Renz, Managing Director & Co-Founder
Address Am Klopferspitz 19
82152 Planegg/Martinsried
Telephone/Telefax +49 89 215 46 375/ +49 6421 98300599
Social media LinkedIn






Hier kostenfrei für den Newsletter anmelden!